Cargando…

Hypersensitivity Reactions to Platinum Agents and Taxanes

Hypersensitivity reactions (HSRs) to chemotherapy agents can present a serious challenge to treating patients with preferred or first-line therapies. Allergic reactions through an immunologic mechanism have been established for platinum and taxane agents, which are used to treat a wide variety of ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsao, Lulu R., Young, Fernanda D., Otani, Iris M., Castells, Mariana C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156473/ https://www.ncbi.nlm.nih.gov/pubmed/34338975 http://dx.doi.org/10.1007/s12016-021-08877-y

Ejemplares similares

Differential outcomes of 609 rapid drug desensitization (RDD) for type I hypersensitivity to platins and taxanes
por: Caiado, Joana, et al.
Publicado: (2014)

Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review
por: Makrilia, Nektaria, et al.
Publicado: (2010)

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
por: Maurer, Kathryn, et al.
Publicado: (2017)

COVID-19 Vaccination in Patients with Documented Reactions to Polyethylene Glycol or Polysorbate
por: Tang, Monica, et al.
Publicado: (2022)

Hypersensitivity Reaction and Tolerance Induction to Ethambutol
por: Cernadas, Josefina Rodrigues, et al.
Publicado: (2013)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics
por: Otani, Iris M., et al.
Publicado: (2022)

Editorial: The Role of Mast Cells in Immediate Hypersensitivity Reactions
por: Aun, Marcelo Vivolo, et al.
Publicado: (2021)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Basophil Activation Test as a Biomarker for Taxanes Anaphylaxis
por: De Campos, Lucila, et al.
Publicado: (2022)

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study
por: Puxeddu, Ilaria, et al.
Publicado: (2021)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Specific questionnaire detects a high incidence of intra-operative hypersensitivity reactions
por: Garro, Laila S., et al.
Publicado: (2018)

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations
por: Castells, Mariana
Publicado: (2017)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008)

Anaphylactic reaction to carboplatin diagnosed by skin testing—a reliable tool in platinum-based immediate-type hypersensitivity reactions
por: Marquart, Elias, et al.
Publicado: (2022)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Drug hypersensitivity reactions in Asia: regional issues and challenges
por: Thong, Bernard Yu-Hor, et al.
Publicado: (2020)

Beyond taxanes: the next generation of microtubule-targeting agents
por: Cortes, Javier, et al.
Publicado: (2011)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

Cascade Metathesis Reactions for the Synthesis of Taxane and Isotaxane Derivatives
por: Ma, Cong, et al.
Publicado: (2016)

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Knoerl, Robert, et al.
Publicado: (2021)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
por: Felisiak-Golabek, Anna, et al.
Publicado: (2011)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches
por: de las Vecillas Sánchez, Leticia, et al.
Publicado: (2017)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis
por: Lee, J, et al.
Publicado: (2013)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_440scf5drkm9ue85drpf1qpjhn